News archive

The JPIAMR activity report now published summarises the achievements of JPIAMR and the major events conducted in the year 2022.

The call “Development of innovative strategies, tools, technologies, and methods for diagnostics and surveillance of antimicrobial resistance” is now open. 

This call aims to fund research projects developing novel or improving existing strategies, tools, technologies and methods for diagnosis and/or One Health AMR surveillance. It involves 22 funding organisations from 18 countries and has a total estimated call budget of 18,8 M€.

The candidate One Health Antimicrobial Resistance partnership (OH AMR) has been identified by the European Commission as one of the candidate European Partnerships of Horizon Europe. Currently, the Research and Innovation Objectives of OH AMR are under preparation, and we now invite researchers, stakeholders, scientists, policymakers, clinicians, patient groups, AMR-related organisations, and others to provide feedback on the elements included in the Research and Innovations Objectives.

Six networks have been recommended for funding within the JPIAMR 15th transnational call: Diagnostics and Surveillance Networks. The networks include 228 partners from 40 countries and for the first time, a network focussed on antifungal resistance has been included.

Thirteen projects involving 72 partners from 15 different countries have been recommended for funding within the JPIAMR 14th transnational call: Disrupting drug Resistance Using Innovative Design. The call was within the framework of the ERA‐NET JPIAMRACTION and the total funding amount is 15,4 M€.

We are pleased to pre‐announce the transnational call “Development of innovative strategies, tools, technologies, and methods for diagnostics and surveillance of antimicrobial resistance”. The call involves 21 funding organisations from 18 countries and has a total estimated call budget of 18,8 M€.

In 2022, the Coordination and Support Action (CSA) DESIGN OH AMR has organised a series of stakeholder and expert consultations to collect input to the update of the research and innovation objectives within the JPIAMR SRIA.

In preparation for the future OH AMR Partnership, JPIAMR invites the research community to share its view on gaps in the AMR funding landscape and the requirements for potential funding mechanisms with impact.

A report on the outputs, outcome and impact generated by the projects funded in the various JPIAMR transnational research project and network calls under the Therapeutics priority topic has been published.

The development of resistance to antibiotics is a biological process, but the context that determines emergence and impact of resistance is underpinned by social aspects. Therefore, it is necessary to identify, understand and evaluate these social aspects to enable the prevention and control of AMR.